Genomic Profiling Using The UltraSEEK Panel Identifies Discordancy Between Paired Primary And Breast Cancer Brain Metastases And An Association With Brain Metastasis-Free Survival

Carlo Palmieri (c.palmieri@liverpool.ac.uk)  
University of Liverpool  
https://orcid.org/0000-0001-9496-2718

Athina Giannoudis  
University of Liverpool Institute of Systems, Molecular and Integrative Biology

Alexander Sartori  
Agena Bioscience

Lee Eastoe  
Agena Bioscience

Rasheed Zakaria  
University of Liverpool Institute of Systems Molecular and Integrative Biology

Christopher Charlton  
Manchester University NHS Foundation Trust

Nicholas Hickson  
Manchester University NHS Foundation Trust

Angela Platt-Higgins  
University of Liverpool, Institute of Systems Molecular and Integrative Biology

Philip S. Rudland  
University of Liverpool

Darryl Irwin  
Agena Bioscience

Michael D. Jenkinson  
University of Liverpool

Research Article

Keywords: UltraSEEK®, mutations, breast cancer, brain metastasis

DOI: https://doi.org/10.21203/rs.3.rs-377753/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose. Brain metastases (BM) are an increasing clinical problem. This study aimed to assess paired primary breast cancers (BC) and BM for aberrations within TP53, PIK3CA, ESR1, ERBB2 and AKT utilising the MassARRAY® UltraSEEK® technology (Agena Bioscience, San Diego, USA).

Methods. DNA isolated from 32 paired primary BCs and BMs was screened using the custom UltraSEEK® Breast Cancer Panel. Data acquisition and analysis was performed by the Agena Bioscience Typer software v4.0.26.74.

Results. Mutations were identified in 91% primary BCs and 88% BM cases. TP53, AKT1, ESR1, PIK3CA and ERBB2 genes were mutated in 68.8%, 37.5%, 31.3%, 28.1% and 3.1% respectively of primary BCs and in 59.4%, 37.5%, 28.1%, 28.1% and 3.1% respectively of BMs. Differences in the mutations within the 5 genes between BC and paired BM were identified in 62.5% of paired cases. In primary BCs, ER-positive/HER2-negative cases harboured the most mutations (70%), followed by ER-positive/HER2-positive (15%) and triple-negatives (13.4%) whereas in BMs, the highest number of mutations was observed in triple-negatives (52.5%), followed by ER-positive/HER2-negative (35.6%) and ER-negative/HER2-positive (12%). There was a significant association between the number of mutations in the primary BC and breast-to-brain metastasis-free survival (p=0.0001) but not with overall survival (p=0.056).

Conclusion. These data demonstrate the discordancy between primary BC and BM, as well as the presence of clinically important, actionable mutations in BCBM. The UltraSEEK® Breast Cancer Panel provides a tool for BCBM that can be utilised to direct more tailored treatment decisions and for clinical studies investigating targeted agents.

Introduction

Breast cancer brain metastasis (BCBM) is a growing clinical problem associated with significant morbidity and mortality. Up to 40–50% of women with HER2-positive and triple negative breast cancers (BC) will develop brain metastasis (BM), whereas its incidence in hormone-receptor positive BC is 14% [1–4]. The application of next generation sequencing technologies has enabled the characterisation of BCs and highlighted that BC subtypes differ in their mutational profiles but overall, the commonest mutated genes are TP53, PIK3CA, GATA3, CDH1, AKT1 [5–10]. Genomic profiling has also demonstrated the complex and diverse molecular landscapes of secondary metastatic BCs [6, 7, 10, 11]. BM sequencing studies have identified differences in their mutational landscape as compared to primary tumours [12–16]. The identification of genomic alterations within BM and the use of targeted therapies against these mutations may improve the clinical outcomes of patients with BCBM [9–16].

In the era of precision medicine and targeted therapies, the choice of anti-cancer therapy is increasingly tailored according to the molecular and/or genomic characterization of the underlying malignancy. Identifying rare and low-level mutations due to tumour heterogeneity in cancer samples and/or of poor-quality DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tissues entails tools that offer both low frequency detection and efficient use of starting material. Such tools could, in turn, be utilised for therapeutic decision making and/or development of clinical trials using targeted agents. The UltraSEEK® (Agena Bioscience, San Diego, USA) technology provides a targeted, multiplexed method for detecting rare events, with detection threshold as low as 0.1% on the MassARRAY® system utilising DNA isolated from FFPE tissues, plasma and cerebrospinal fluid [17–20]. Moreover, multiplex detection of low-frequency mutations is becoming a necessary diagnostic tool for clinical laboratories that must overcome several challenges such as the detection of minor alleles among abundant wild-types, the heterogeneous nature of the tumours and the limited amount of available tissue [17–20]. The UltraSEEK® Breast Cancer panel has been developed to enable the assessment of five commonly mutated genes in breast cancer, TP53, PIK3CA, ERBB2, ESR1
and AKT1. This study aimed to assess the mutational landscape of paired BC and BMs for these known key genomic drivers, utilising the UltraSEEK® BC panel.

**Materials And Methods**

**Patients:**

A total of 32 FFPE primary BC samples, with their paired BMs were collected from the Liverpool Tissue Bank and the Walton Research Tissue Bank (WRTB) Liverpool, UK. The cases were stained by immunohistochemistry (IHC) for hormone-receptor expression (ER, PgR) and HER2 as previously described [21]. The study was performed in accordance with the Declaration of Helsinki and approved by the WRTB (WRTB 15_06) and the National Research Ethics Committee (NRES 11/ WN003/2). Written consent was in place before anonymised tissue and data were released for research purposes [21].

**DNA Extraction and Mutation Profiling:**

DNA was isolated from 32 BC and their matched BM cases using the GeneRead DNA FFPE kit (Qiagen, Crawley, UK) and screened using the custom UltraSEEK BC Panel (Agena Bioscience, San Diego, USA). Starting from a single global multiplex polymerase chain reaction (PCR) the panel tests 39 mutations (Table 1) across 5 oncogenes (TP53, PIK3CA, ESR1, ERBB2 and AKT) in 8 multiplex assays (Supplementary table 2). PCR was performed using 10 ng of DNA according to the manufacturer’s instructions (Agena Bioscience, San Diego, USA). Amplified products were treated with shrimp alkaline phosphatase (SAP) and the PCR/SAP product was aliquoted in a new 96-well plate for downstream extension and termination reaction according to the manufacturer’s instructions. The single-base extended oligonucleotides were captured by streptavidin-coated magnetic beads and biotin-labelled following manufacturer’s instructions. The products were then transferred to the MassARRAY System with Chip Prep Module 96 (CPM96) that automatically performs desalting (resin), transfer of analyte and calibrant to the SpectroCHIP® Arrays and loading of SpectroCHIP® Arrays. Data were automatically acquired using the MassARRAY Analyzer. The workflow is presented and summarised in Supplementary figure 1.

**Data Analysis and Statistics:**

Data was analysed using the Typer software v4.0.26.74 (Agena Bioscience, San Diego, USA). The signal intensity of the mutant allele was normalized against the capture-control peaks (biotin-labelled, non-reactive oligos, used as an internal control) as previously reported.\(^{17,18}\) Samples with a mutant allele-call with a signal-to-noise ratio ≥ 6 and a z-score ≥ 7 were considered positive for the mutation. Positive mutan-calls with z-scores 7-10 were labelled ‘L’ (low-level confidence) to distinguish from the results with high-level confidence (T), z-score >10 [17-19]. The z-score is a robust scoring representing the deviation of the minor allele’s frequency from the median baseline frequency, as measured by median absolute deviation (MAD) units. The baseline signal distribution or population of that peak is generated by analysing a population of known wild-type samples for each target and capture pre-analytical and background noise inherent to the assay and analyte. The UltraSEEK chemistry and methodology has been analytically presented by Mosko et al [18].

RAWGraphs (https://rawgraphs.io/) was used to generate the alluvial diagram illustrating the receptor switching between the primary and metastatic setting. Fisher’s Exact test was used to compare the receptor status change versus the number of mutation (≤3 vs >3) in the primary BC and Wilcoxon signed-rank paired t-test (Gaussian approximation) was used to compare the total number of mutations between the paired BC and BMs. Kaplan-Meier
(Log-rank) survival analysis was used to determine whether the number of mutations in the primary BC and the receptor status change between BCs and BMs was associated with the breast-brain metastasis-free survival (BMFS, time between the initial breast surgery and the resection of the BM) and overall survival (OS, time between breast diagnosis/surgery and death from any cause). Statistical analysis was performed on GraphPad Prism v5.0 (GraphPad Inc, San Diego, USA).

The OncoKB (http://oncoKB.org) and ClinicalTrials.gov (https://clinicaltrials.gov) databases were used to identify actionability and ongoing clinical trials on BC using targeted-therapies for the mutated genes in this study. The searches on OncoKB were performed for Breast Cancer, Actionable Genes and the following Levels of Evidence: 1. FDA-approval, 2. Standard care, 3. Clinical evidence, 4. Biological evidence, R1/R2. Resistance. The searches on the ClinicalTrials.gov were performed for Breast Cancer, Recruiting, Active (not recruiting), Completed, Adult and selecting for specific gene mutations/alterations for PIK3CA, AKT1, ESR1, ERBB2/HER2 and TP53. Similar work on BCBM mutated genes was recently presented by our group in a systematic review [13].

Results

Patient Characteristics and Receptor Switching:

Amongst the 32 primary BCs, 18 (56.2%) were ER-positive/HER2-negative, 4 (12.5%) were ER-positive/HER2-positive, 3 (9.4%) were ER-negative/HER2-positive and 7 (21.9%) were triple-negative (TN). Eight of the 18 (44.4%) ER-positive and all the 4 (100%) ER-positive/HER2-positive primary BCs lost ER expression in BM. The HER2-positive and TN primary BCs maintained their receptor status in the BM. The changes of the receptor status between BCs and their paired BMs are illustrated in the alluvial diagram (Figure 1A).

Mutational profiling and receptor status change

A mutation in any of the five genes was identified in 29 of 32 (90.6%) primary BCs and 28 of 32 (87.5%) BM cases. A total number of 67 and 59 mutations were detected in primary BCs and their paired BMs respectively without significant association in the number of mutations between the paired BC and BM cases (p=0.424, median 2 in both BC and BM, Figure 1B). The total number of mutations in each gene, including percentages, is illustrated in Figure 1C and Supplementary Table 3. We observed that in 20 of 32 (62.5%) paired cases there were differences in the total number of mutations between the primary BC and paired BM with 11 of 32 (34.4%) and 9 of 32 (28.1%) cases showing either a reduction or increase in the total number of mutations respectively in the paired BMs. In 12 of 32 (37.5%) paired cases the number of mutations did not differ. The scatter-plot showing the number of mutation changes between pairs is illustrated in Figure 1D. Out of the 32 paired BCs and BMs, TP53, AKT1, ESR1 and PIK3CA genes were respectively mutated in 22 (68.8%), 12 (37.5%), 10 (31.3%) and 9 (28.1%) of the primary BCs and in 19 (59.4%), 12 (37.5%), 9 (28.1%) and 9 (28.1%) of the BMs. ERBB2 mutations were detected in 1 out of 32 (3.1%) BC and BM cases. The genomic landscape of the paired BC and their BMs for the individual mutations and the confidence level of detection (T or L) for each one is presented in a matrix format in Figure 2. Mutations were detected with similar confidence (T/T and/or L/L) in 18 of 32 (56.3%) paired BC and BM cases and increased to 21 of 32 (65.6%) when mutations with different confidence (L/T) between paired BC and BM cases were included, highlighting the differences in the genomic landscape between primary BC and paired BM. For instance, the AKT1 pE17K mutation was detected in 10 of 32 (31.25%) paired cases; 8 of 32 (25%) with the same confidence levels and 2 of 32 (6.3%) cases with low confidence (L) in the primary and high confidence (T) in paired BM (Figure 2). The TP53 pR273H was the more prevalent mutation in both BC and BM cases present in 4 of 32 (12.5%) paired cases, 3 of which with similar confidence and 1 with lower confidence in BC than BM, 3 (9.4%) primary BCs and 3 (9.4%) BMs.
(Figure 2). Representative examples of the different mutation spectra highlighting the differences in the confidence levels (T/T, T/L, -/T) are presented in Figure 3A.

The 32 primary BCs contained a total of 67 mutations and hormone receptor-positive cases harboured the most mutations (47/67; 70%), followed by ER-positive/HER2-positive (10/67; 15%) and triple-negatives (9/67; 13.4%) whereas in BMs with a total of 59 mutations, the highest number was observed in triple-negatives (31/59; 52.5%), followed by hormone receptor-positive (21/59; 35.6%) and HER2-positive (7/59; 12%). Of the 32 primary BCs, 27 (84.37%) had 3 or less mutations (≤3) and 9 of these 27 (33.3%) change status in BM whereas 18 (66.7%) maintain their receptors. Of the 5 (15.63%) primary BCs with >3 mutations, 3 (60%) change status in BM and 2 (40%) maintain their receptors. There was no significant association between the receptor switching and the number of mutations identified by two-tail Fisher’s exact test (p=0.337). The number of patients, the total number of mutations and the number of mutations in each gene according to the receptor status of BC and BM are presented in Supplementary Table 3. All the mutation frequencies for the primary BCs and BMs according to the receptor status are illustrated in Figure 3B.

**Mutations and clinical significance**

Patients with primary BCs with ≤3 mutations had a significantly longer BMFS, than patients whose BCs had >3 mutations with median BMFS of 28.5 and 12 months respectively (HR:0.011, 95% CI:0.001-0.112; p=0.0001, Figure 3C). There was no association with OS although the median OS was 53 and 29 months in patients carrying ≤3 and >3 mutations respectively (HR:0.146, 95% CI:0.020-1.054, p=0.056, Figure 3C). When the patients were classified according to the change in ER, PgR and HER2 status between primary BC and BM the median survival was 24.5 (receptor change) and 29.5 (no change) months but no significant association was observed with either BMFS (p=0.115) or OS (p=0.618).

**Actionability of mutated genes**

A search on oncoKB for the actionability of PIK3CA, AKT1, ESR1, and ERBB2/HER2 oncogenic mutations on BC identified 7 protocols, 3 of which are FDA-approved (Alpelisib, Neratinib and Abemaciclib. No protocols were identified for TP53 (Table 2).

Forty-three clinical trials are currently available for BC patients with mutations in these 5 genes as identified within ClinicalTrials.gov (Supplementary Table 4) whereas twelve trials specifically recruiting patients with BCBM using targeted-therapies for the identified gene mutations/alterations were recently reported [13]. Drugs targeting PIK3CA [Paxalicib (GDC-0084), Buparlisib (BMK120)], ERBB2/HER2 (Neratinib, Afatinib, Pyrotinib, Tucatinib), pathways and/or genes involved in the cell cycle (Abemaciclib, NKTR-102) are currently undergoing assessment in clinical trials either as single agents or in combination with standard of care treatments for BCBM [13].

**Discussion**

In this study, we assessed for the presence of mutations within key BC genes utilising the UltraSEEK® technology in a paired cohort of BCs and BMs. A mutation in at least one of the five genes (TP53, PIK3CA, ERBB2, ESR1, AKT1) was identified in most cases, with 90.6% of primary BC and 87.5% of the paired BMs having at least one mutation. The observed similarities regarding the frequency of the mutated genes reflect the nature of the UltraSEEK® BC panel that was designed to target actionable genes present in all the key BC subtypes. The actionability of these mutated genes in primary BC and BM is presented in Table 2 and in a recent systematic review [13]. The detection of ESR1 mutations in the primary tumours also highlights the sensitivity of the assay [18]. Although ESR1 mutations
were more commonly identified in metastatic BCs [22, 23], the use of the sensitive droplet-digital PCR reported higher frequencies in primary tumours [24, 25]. The identification of therapeutic strategies in breast cancers harbouring ESR1 mutants is an area of active interest. Fulvestrant has demonstrated poor clinical activity in ESR1-mutated BC [26, 27], whereas bazedoxifene and lasofoxifene have demonstrated activity in pre-clinical models of ESR-mutated BC [28, 29]. The efficacy of lasofoxifene is currently being explored in the ELAINE trial (NCT03781063) in patients with ESR1-mutated BCs (Supplementary table 4). Interestingly, in our cohort, ESR1 mutations were seen in 28.1% of BMs despite the loss of ER expression by IHC, indicating that the ESR1-mutant clones are likely dominant clones, resistant to therapy [22–25, 27]. These results are in accordance with others who detected a high ESR1 mutation frequency (34.3–44.9%) in BMs [24].

While TP53 is mutated in all BC subtypes, it is most common in TNs and HER2 [3, 30–32]. TP53 mutations have been associated with worse clinical outcomes and poor response to hormonal therapy, chemotherapy and/or radiotherapy [30–33] and our samples have been acquired from patients who had progressed and developed brain metastasis despite prior treatment. TP53 can be re-activated by targeting molecules that modulate its posttranslational modifications, localization and degradation and several ongoing clinical trials are using TP53-reactivating compounds in combination with chemotherapeutic drugs (Supplementary table 4) [34, 35].

ERBB2/HER2 mutations were identified in only 2 samples, a primary ER-positive BC and a HER2-positive BM. These ERBB2/HER2 mutations are associated with resistance to lapatinib but are sensitive to neratinib, highlighting the importance of treating HER-mutated cancers with the appropriate HER-targeted drugs (Table 2, Supplementary table 4) [36, 37]. The identification of mutations in PIK3CA and AKT1 are also of clinical significance since both genes are druggable (Table 2, Supplementary table 4). The PI3Kα-specific inhibitor alpelisib, has shown activity in PIK3CA-mutant breast cancers (NCT02437318) and recently granted FDA and European commission approval while its potential in the regression and stabilisation of progressive BCBM has been highlighted [38, 39]. The brain-penetrant inhibitor paxalisib (GDC-0084) has demonstrated activity in pre-clinical models of BCBM [40]. Several inhibitors targeting the AKT1 pE17K mutation, an oncogenic driver in BC, have shown efficacy as monotherapy or in combination with other drugs (Table 2, Supplementary table 4) [41–43]. We recently presented a summary of current clinical trials on mutated BCBMs [13].

Several studies have identified large similarities in the mutational profiles of primary tumours and their metastases including BMs [5–10], whereas others showed clear differences between primary and metastasis in the numbers and types of mutations [11–14]. It was recently suggested that the systemic metastatic seeding can begin early during primary tumour growth and that the clonal architecture is remodelled by treatment that may select for disseminated cells harbouring resistant mutations [44]. Treatment was also associated with high gene heterogeneity and monoclonal metastases [44]. Similarly, within our cohort of paired BC and BM cases, the median BMFS time (irrespectively of mutation status) was 26 months and certain gene mutations were detected with similar confidence levels in 56.3% of paired cases (monoclonal metastases). We also identified cases where the mutation was absent or present with low confidence in the primary and with high confidence in the BM and vice versa. The fact that only 37.5% of mutations in the 5 chosen genes are conserved between the primary and just one major metastatic site, the brain, suggests that, in general, compounds targeting these mutations identified solely in the primary breast tumour are unlikely to be successful in the majority of advanced/metastatic patients. Therefore, it seems to be necessary to sample metastases as well as the primary tumour to identify somatic mutations common to tumours at both sites, to predict more accurately whether a patient will respond to such chemical interventions. The differences in the mutational landscape could be attributed to the clonal evolution process, the selective pressure of different therapeutic regimes and the receptor switching between primary BC and metastasis. Evidence of clonal remodelling
between primary tumours and metastases associated with the clinical subtype conversion was recently presented, but the most frequently mutated genes in primary tumours were also identified in metastases independent of the tumour subtype [11]. We did not observe significant differences in the frequently mutated genes in relation to the subtypes in BC and BM and there was no significant association between receptor switching and number of mutations. This could also be attributed to the small number of genes present in the targeted BC mutation panel and the small number of mutations identified in our cohort. Nevertheless, within our cohort, patients carrying \( \leq 3 \) mutations had a significantly better BMFS \( (p = 0.0001) \), than patients with \( > 3 \) mutations indicating that the higher number of mutations correlates to worst prognosis (metastasis-free survival).

A limitation of the MassARRAY UltraSEEK technology in comparison to next generation sequencing on the identification of mutations is the use of predefined mutations across different oncogenes. Although, it cannot detect unknown mutations and copy number alterations, it is more cost-effective and could be easier applied in a clinical setting [20, 45, 46]. Moreover, the challenges to obtain BM samples for sequencing including the inherent risks of neurosurgery, as samples can only be taken when surgical resection is clinically indicated, make longitudinal studies of the changes in the BM genome unethical. The alternative use of circulating cell-free DNA (cfDNA) in the CSF and plasma is under investigation and in the future patients will be able to have tailored treatments based on the results of sequencing cfDNA from CSF rather than relying on the genomics of the primary lesion [19, 45, 46].

In summary, our data highlights the presence of clinically important and actionable mutations in AKT1, ESR1, PIK3CA, TP53 and ERBB2 genes in BC and in BCBM as identified by the UltraSEEK BC panel that provides a powerful tool to investigate low abundance mutations and could be potentially useful in a clinical environment [24, 25]. These mutations could be used to identify patients resistant to certain therapeutic regimes and enable the development of more tailored clinical studies utilising targeted agents or combinations of them in the brain metastatic setting.

**Abbreviations**

BC: Breast cancer

BCBM: Breast cancer brain metastasis

BM: Brain metastasis

BMFS: Breast-brain metastasis-free survival

CPM96: Chip Prep Module 96

ER: Estrogen receptor

FFPE: Formalin-fixed, paraffin-embedded

HER2: Human epidermal growth factor receptor 2

IHC: Immunohistochemistry

OS: Overall survival

PCR: Polymerase chain reaction

PgR: Progesterone receptor
SAP: Shrimp alkaline phosphatase

TN: Triple-negative

UNG: Uracil-DNA glycosylase

**Declarations**

**Competing Interests**

The authors declare no conflicts of interest.

**Funding**

The UltraSEEK Breast Cancer panel, assays and reagents were kindly provided from Agena Bioscience GmbH, Hamburg, Germany

**Ethics Statement and Informed Consent**

The study was performed in accordance with the Declaration of Helsinki and approved by the WRTB (WRTB15_06) and the National Research Ethics Committee (NRES 11/WN003/2). Written consent was in place before anonymised tissue and data were released for research purposes.

**Acknowledgments**

We would like to acknowledge the Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (Grant Reference: C18616/A25153) and the Clatterbridge Cancer Charity and the Liverpool University Hospitals NHS Foundation Trust for support.

**Data Availability**

All data generated or analysed during this study are included in this published article and its supplementary information files.

**Authors Contributions**

All authors contributed to the experimental design, its implementation, analysis and interpretation of the data. All authors were involved in the writing of the manuscript and have read and approved the final version. **AG:** Conceptualization, Investigation, Formal analysis, Writing and Editing. **AS:** Methodology, Software, Validation, Data Curation, Writing and Editing. **LE:** Methodology, Software, Validation. **RZ:** Formal Analysis, Writing and Editing. **CC:** Investigation, Resources. **NH:** Resources, Investigation, Data Curation. **APH:** Investigation. **PSR:** Resources, Writing and Editing. **DI:** Methodology, Software, Validation, Resources. **MDJ:** Resources, Writing and Editing. **CP:** Conceptualization, Resources, Writing and Editing, Supervision.

**References**

1. Nam B-H, Kim SY, Han H-S et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10:R20
2. Berghoff A, Bago-Horvath Z, De Vries C et al (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106:440–446

3. Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663

4. Heitz F, Harter P, Lueck HJ et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792–2798

5. Angus L, Smid M, Wilting SM et al (2019) The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet 51:1450–1458

6. Bertucci F, Ng CKY, Patsouris A et al (2019) Genomic characterization of metastatic breast cancers. Nature 569:560–564

7. Lefebvre C, Bachelot T, Filleron T et al (2016) Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med 13:e1002201

8. Pereira B, Chin S-F, Rueda OM et al (2016) The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat Communications 7:11479

9. Nik-Zainal S, Morganella S (2017) Mutational Signatures in Breast Cancer: The Problem at the DNA Level. Clin Cancer Res 23:2617–2629

10. Muller KE, Marotti JD, de Abreu FB et al (2016) Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers. Exp Mol Pathol 100:421–425

11. Lluch A, Gonzalez-Angulo AM, Casadevall D et al (2019) Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer 120:54–64

12. Brastianos PK, Carter SL, Santagata S et al (2015) Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov 5:1164–1177

13. Morgan A, Giannoudi A, Palmieri C (2021) The genomic landscape of breast cancer brain metastases: a systematic review. Lancet Oncol 22:E7–E17

14. De Mattos-Arruda L, Mayor R, Ng CKY et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839

15. Lee JY, Park K, Lim SH et al (2015) Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget 6:43731–43742

16. Saunus JM, Quinn MC, Patch AM et al (2015) Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol 237:363–378

17. Fleitas T, Ibarrola-Villava M, Ribas G, Cervantes A (2016) MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalised medicine. Cancer Treat Rev 49:57–64

18. Mosko MJ, Nakorchevsky AA, Flores E et al (2016) Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry. J Mol Diagn 18:23–31

19. Gray ES, Witkowski T, Pereira M et al (2019) Genomic analysis of circulating tumour DNA using a melanoma-specific UltraSEEK oncogene panel. J Mol Diagn 21:418–426

20. Toomey S, Carr A, Mezynski MJ et al (2020) Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. J Trans Med 18:99
21. Giannoudis A, Clarke K, Zakaria R et al (2019) A novel panel of differentially expressed microRNAs in breast cancer brain metastasis may predict patient survival. Sci Rep 9:18518
22. Toy W, Weir H, Razavi P et al (2017) Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov 7:277–287
23. Lei JT, Gou X, Seker S, Ellis MJ (2019) ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat 5:38
24. Wang P, Bahreini A, Gyanchandani R et al (2016) Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res 22:1130–1137
25. Gelsomino L, Gu G, Rechoum Y et al (2016) ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat 157:253–265
26. Macpherson I, Kilburn L, Kernaghan S et al (2020) Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010). Cancer Res 80:P1-19-04
27. Spoerke JM, Gendreau S, Walter K et al (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579
28. Fanning SW, Jeselsohn R, Dharmarajaet V et al (2018) The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. eLife 7:e37161
29. Andreano KJ, Baker JG, Park S et al (2020) The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor. Mol Cancer Ther 19:1395–1405
30. Silwal-Pandit L, Vollan HK, Chin SF et al (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20:3569–3580
31. Dobes P, Podhorec J, Coufal O et al (2014) Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep 32:1695–1702
32. Basho RK, de Melo Gagliato D, Ueno NT et al (2016) Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7:76362–76373
33. Ungerleider NA, Rao SG, Shahbandi A et al (2018) Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res 20:115
34. Ladds MJGW, Lain S (2019) Small molecule activators of the p53 response. J Mol Cell Biol 11:245–254
35. Sanz G, Singh M, Peuget S et al (2019) Inhibition of p53 inhibitors: progress, challenges and perspectives. J Mol Cell Biol 11:586–599
36. Bose R, Kavuri SM, Searleman AC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224–237
37. Cocco E, Lopez S, Santin AD, Scaltriti M (2019) Prevalence and role of HER2 mutations in cancer. Pharmacol Ther 199:188–196
38. André F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929–1940
39. Batalini F, Moulder SL, Winer EP et al (2020) Response of brain metastases from PIK3CA-mutant breast cancer to Alpelisib. JCO Prec Oncol 4:572–578
40. Ippen FM, Alvarez-Breckenridge CA, Kuter BM et al (2019) The Dual PI3K/mTOR pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases. Clin Cancer Res 25:3374–3383
41. Rudolph M, Anzeneder T, Schulz A et al (2016) AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer 16:622
42. Davies BR, Guan N, Logie A et al (2015) Tumors with AKT1 E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. Mol Cancer Ther 14:2441–2451
43. Hyman DM, Smyth LM, Donoghue MTA et al (2017) AKT Inhibition in solid tumors with AKT1 mutations. J Clin Oncol 35:2251–2259
44. Hu Z, Li Z, Ma Z, Curtis C (2020) Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumours and metastases. Nat Genet 52:701–708
45. Gorges K, Wiltfang L, Gorges TM et al (2019) Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers 11:1685
46. Belloum Y, Janning M, Mohme M et al (2020) Discovery of targetable genetic alterations in NSCLC patients with different metastatic patterns using a MassARRAY-based circulating tumor DNA assay. Cells 9:2337

Tables

**Table 1. UltraSEEK Breast Cancer Panel.** The UltraSEEK BC panel screens for 39 mutations across 5 common BC oncogenes.

| Genes      | Missense Mutations                  | No of Mutations |
|------------|-------------------------------------|-----------------|
| AKT1       | pE17K*, pL52R*                       | 2               |
| ERBB2/HER2 | pG309A, pG309E, pS310F*, pL755R, pL755S, pL755S_T759del, pD769H*, pD769Y, pV777L*, pL869R* | 10              |
| ESR1       | pA283V, pK303R, pE380Q*, pV392I, pS463P, pL536R, pL536Q, pY537C, pY537N*, pY537S, pD538G, pS576L | 12              |
| PIK3CA     | pN345K, pC420R*, pE542K*, pE545A, pE545K*, pE545Q, pH1047L*, pH1047R | 8               |
| TP53       | pR175H, pR213X, pY220C, pR248Q, pR248W*, pR273C, pR273H | 7               |
| Total      | 5 genes                             | 39              |

* Multiple assays for these mutations are included in the panel.

**Table 2: OncoKB database and gene actionability.** A search on the oncoKB for the actionability of PIK3CA, AKT1, ESR1, ERBB2/HER2 and TP53 oncogenic mutations on Breast Cancer identified 7 protocols. 1. FDA-approval, 3. Clinical evidence, *NA: Not available.
| Level | Alteration: Oncogenic Mutations | No of Mutations (%) | Drugs | Citations |
|-------|--------------------------------|---------------------|-------|-----------|
|       |                                | BC (N=32) BM (N=32) |       |           |
| 1     | PIK3CA                          | 10 (15) 10 (17)     | Alpelisib + Fulvestrant | 3 PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Bosch A et al. Sci Transl Med. 2015 PMID: 25877889 Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. Juric D et al. JAMA Oncol. 2019 PMID: 30543347 Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. André F et al. N Engl J Med. 2019 PMID: 31091374 |
| 3A    |                                | GDC-0077            | 3     | 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2− LA/MBC). TurnerN et al. Annals Onc. 2020 DOI: https://doi.org/10.1016/j.annonc.2020.08.457 Juric D et al. Abstract# OT1-08-04, SABCS 2019 Hong R et al. Abstract# PD4-14, SABCS 2017 |
| 3     |                                | Copanlisib + Fulvestrant | 7     | First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Patnaik A et al. Ann Oncol. 2016 PMID: 27672108 Exceptional Response to Copanlisib in a Heavily Pretreated Patient With PIK3CA-Mutated Metastatic Breast Cancer. Spathas N et al. JCO Prec Onc. 2020 https://doi.org/10.1200/PO.19.00049 Staben et al. Abstract# DDT02-01, AACR 2017 De et al. Abstract# 3438, AACR 2019 O’Brien, NA et al. Abstract P3-04-15. Cancer Research, 2017 De et al. Abstract# P2-03-08, SABCS 2018 Edgar et al. Abstract# 156, AACR 2017 |
| 3     | AKT1                            | 12 (18) 12 (20.3)   | AZD5363 | 4 Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of |
monotherapy activity with genetic background. Davies BR et al. Mol Cancer Ther. 2012 PMID: 22294718

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. Addie M et al. J Med Chem. 2013 PMID: 23394218

AKT Inhibition in Solid Tumors With AKT1 Mutations. Hyman DM et al. J Clin Oncol. 2017 PMID: 28489509

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Davies BR et al. Mol Cancer Ther. 2015 PMID: 26351323

|   | ERBB2/HER2 |   |   |   |   |   |   |   |   |
|---|------------|---|---|---|---|---|---|---|---|
| 1 | ERBB2/HER2 | 1 (1.5) | 1 (1.7) |   |   |   |   |   |   |
|   | Neratinib   |   |   |   |   |   |   |   |   |
| 3 | ESR1       | 13 (19.4) | 11 (18.6) |   |   |   |   |   |   |
|   | AZD9496     | 2   |   |   |   |   |   |   |   |

Activating HER2 mutations in HER2 gene amplification negative breast cancer. Bose R et al. Cancer Discov. 2013 PMID: 23220880

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Minami Y et al. Oncogene. 2007 PMID: 17311002

HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Hyman DM et al. Nature. 2018 PMID: 29420467

|   | Abemaciclib + Fulvestrant |   |   |   |   |   |   |   |   |
|---|---------------------------|---|---|---|---|---|---|---|---|
| 1 |   |   |   |   |   |   |   |   |   |

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer. Gil-Sierra MD et al. JAMA Oncol. 2020 doi:10.1001/jamaoncol.2020.1516

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. Sledge GW Jr et al. JAMA Oncol. 2019 PMID: 31563959

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Toy W
Figures

C.

[Bar chart showing total number of mutations per gene for different genes such as AKT1, ERBB2, ESR1, PIK3CA, and TP53. The chart compares BC and BM samples.]

D.

[Scatter plot showing number of mutations per patient against patient IDs, with bars indicating BC and BM cases.]

Figure 1

Parts A and B are not available with this version. Receptor switch and mutation detection in paired BC and BM samples. A. The Alluvial diagram illustrates the receptor (ER, PgR, HER2) switch between primary BC and their paired BM cases including % for each subtype. B. No significant association was identified (p=0.484) in the number of mutations between primary BCs and their paired BMs. C. Total number of mutations per gene identified in both BC.
(blue) and BM (red) samples. The percentage of each mutation over the total number of mutations is presented on the top of each bar and on supplementary table 3. D. Scatter-plot showing the number of mutations for each pair. Blue dots-lines and red dots-lines represent the number of mutations changing between BC and from BM. Black dots represent the cases with similar number of mutations in both the primary BC and its paired BM.

**Figure 2**

The genomic landscape of BCBM using the UltraSEEK Breast Cancer Panel. The illustrated matrix presents paired BC and BM patients IDs, the genes with the identified mutations, the multiplex assays (purple indicates that 2 assays were run for these mutations) and the confidence call of the mutations. T (green): High level confidence call = high signal intensity and z-score >10, L (red): Low level confidence call = low signal intensity and z-score 7-10. The total number of mutations, the breast-brain metastasis-free (BMFS) and the BM-to-death survival (both in months) and the receptor status are also presented. *: Synchronous, NA: Not available.
Figure 3

Mutation detection in paired BC and BM samples. A. Representative examples of mutation spectra between paired BC/BM samples with identified mutations as (i) T/T, (ii) T/L and (iii) (-/T) with relative intensity on the y-axis and mass/charge on the x-axis. B. The frequency (percentages) of the identified mutations for each of the 5 genes according to the ER, PgR and HER2 receptor status in primary BC and in paired BM. The exact number of mutations is presented in Supplementary Table 4. One of the 3 ER-negative/HER2-positive primary BC samples was carrying an ESR1 mutation whereas no mutations were identified in the other 2 samples and they were not included in the pie-charts. C. Kaplan-Meier survival plots of breast-brain metastasis-free survival (BMFS) and overall survival (OS). Patients carrying ≤3 mutations had a significantly better BMFS (\( p=0.0001, \) HR:0.011, 95% CI:0.001-0.112), than
patients with >3 mutations. There was no association with OS (p=0.056, HR:0.146, 95% CI:0.020-1.054) and number of mutations.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- AGSupplementaryFigureandTables.docx